BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 22405557)

  • 1. An assessment of prime-boost vaccination schedules with AS03A -adjuvanted prepandemic H5N1 vaccines: a randomized study in European adults.
    Gillard P; Caplanusi A; Knuf M; Roman F; Walravens K; Moris P; Dramé M; Schwarz TF
    Influenza Other Respir Viruses; 2013 Jan; 7(1):55-65. PubMed ID: 22405557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term booster schedules with AS03A-adjuvanted heterologous H5N1 vaccines induces rapid and broad immune responses in Asian adults.
    Gillard P; Chu DW; Hwang SJ; Yang PC; Thongcharoen P; Lim FS; Dramé M; Walravens K; Roman F
    BMC Infect Dis; 2014 Mar; 14():142. PubMed ID: 24628789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults.
    Nagai H; Ikematsu H; Tenjinbaru K; Maeda A; Dramé M; Roman FP
    BMC Infect Dis; 2010 Nov; 10():338. PubMed ID: 21108818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I; Roman F; Forgus S; Maes C; De Boever F; Dramé M; Gillard P; van der Most R; Van Mechelen M; Hanon E; Leroux-Roels G
    Vaccine; 2010 Jan; 28(3):849-57. PubMed ID: 19835828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity of heterologous H5N1 influenza booster vaccination 6 or 18 months after primary vaccination in adults: a randomized controlled clinical trial.
    Langley JM; Frenette L; Jeanfreau R; Halperin SA; Kyle M; Chu L; McNeil S; Dramé M; Moris P; Fries L; Vaughn DW
    Vaccine; 2015 Jan; 33(4):559-67. PubMed ID: 25448092
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single dose vaccination with AS03-adjuvanted H5N1 vaccines in a randomized trial induces strong and broad immune responsiveness to booster vaccination in adults.
    Schwarz TF; Horacek T; Knuf M; Damman HG; Roman F; Dramé M; Gillard P; Jilg W
    Vaccine; 2009 Oct; 27(45):6284-90. PubMed ID: 19856521
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of Prime-boost Vaccination Using an AS03B-adjuvanted Influenza A (H5N1) Vaccine: A Randomized Trial in Children of Three to Less Than Eighteen Years of Age.
    Izurieta P; Uy-Aragon MJ; Dramé M; Vaughn DW
    Pediatr Infect Dis J; 2016 Feb; 35(2):e35-47. PubMed ID: 26551446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heterologous prime-boost vaccination using an AS03B-adjuvanted influenza A(H5N1) vaccine in infants and children<3 years of age.
    Nolan T; Izurieta P; Lee BW; Chan PC; Marshall H; Booy R; Drame M; Vaughn DW
    J Infect Dis; 2014 Dec; 210(11):1800-10. PubMed ID: 24973461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of the humoral and cellular immune response of an H5N1 adjuvanted influenza vaccine in elderly persons: 2-year follow-up of a randomised open-label study.
    Gillard P; Giet D; Heijmans S; Dramé M; Walravens K; Roman F
    Trials; 2014 Oct; 15():419. PubMed ID: 25354581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity and safety of an AS03-adjuvanted H5N1 pandemic influenza vaccine in Korean adults: a phase IV, randomized, open-label, controlled study.
    Izurieta P; Kim WJ; Wie SH; Lee J; Lee JS; Dramé M; Vaughn DW; Schuind A
    Vaccine; 2015 Jun; 33(24):2800-7. PubMed ID: 25910919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II, randomized, open, controlled study of AS03-adjuvanted H5N1 pre-pandemic influenza vaccine in children aged 3 to 9 years: follow-up of safety and immunogenicity persistence at 24 months post-vaccination.
    Díez-Domingo J; Baldó JM; Planelles-Catarino MV; Garcés-Sánchez M; Ubeda I; Jubert-Rosich A; Marès J; Garcia-Corbeira P; Moris P; Teko M; Vanden Abeele C; Gillard P
    Influenza Other Respir Viruses; 2015 Mar; 9(2):68-77. PubMed ID: 25652873
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 2 Clinical Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of Different Prime-Boost Vaccination Schedules of 2013 and 2017 A(H7N9) Inactivated Influenza Virus Vaccines Administered With and Without AS03 Adjuvant in Healthy US Adults.
    Rostad CA; Atmar RL; Walter EB; Frey S; Meier JL; Sherman AC; Lai L; Tsong R; Kao CM; Raabe V; El Sahly HM; Keitel WA; Whitaker JA; Smith MJ; Schmader KE; Swamy GK; Abate G; Winokur P; Buchanan W; Cross K; Wegel A; Xu Y; Yildirim I; Kamidani S; Rouphael N; Roberts PC; Mulligan MJ; Anderson EJ
    Clin Infect Dis; 2024 Jun; 78(6):1757-1768. PubMed ID: 38537255
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical phase I study of an EB66 cell-derived H5N1 pandemic vaccine adjuvanted with AS03.
    Naruse T; Fukuda T; Tanabe T; Ichikawa M; Oda Y; Tochihara S; Kimachi K; Kino Y; Ueda K
    Vaccine; 2015 Nov; 33(45):6078-84. PubMed ID: 26409141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older.
    Van Damme P; Kafeja F; Bambure V; Hanon E; Moris P; Roman F; Gillard P
    Hum Vaccin Immunother; 2013 Jul; 9(7):1512-22. PubMed ID: 23571166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
    Poder A; Simurka P; Li P; Roy-Ghanta S; Vaughn D
    Vaccine; 2014 Feb; 32(9):1121-9. PubMed ID: 24252703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined administration of MF59-adjuvanted A/H5N1 prepandemic and seasonal influenza vaccines: long-term antibody persistence and robust booster responses 1 year after a one-dose priming schedule.
    Lopez P; Caicedo Y; Sierra A; Tilman S; Clemens R; Banzhoff A
    Clin Vaccine Immunol; 2013 May; 20(5):753-8. PubMed ID: 23536690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.
    Langley JM; Reich D; Aggarwal N; Connor D; Lebel MH; Gupta A; Garfield H; Li P; Madan A; Vaughn DW
    Pediatr Infect Dis J; 2012 Aug; 31(8):848-58. PubMed ID: 22801094
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Homologous and heterologous antibody responses to a one-year booster dose of an MF59(®) adjuvanted A/H5N1 pre-pandemic influenza vaccine in pediatric subjects.
    Vesikari T; Forstén A; Borkowski A; Gaitatzis N; Banzhoff A; Clemens R
    Hum Vaccin Immunother; 2012 Jul; 8(7):921-8. PubMed ID: 22777094
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.
    Yang WH; Dionne M; Kyle M; Aggarwal N; Li P; Madariaga M; Godeaux O; Vaughn DW
    Vaccine; 2013 Sep; 31(40):4389-97. PubMed ID: 23856331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization and long-term persistence of immune response following two doses of an AS03A-adjuvanted H1N1 influenza vaccine in healthy Japanese adults.
    Ikematsu H; Nagai H; Kawashima M; Kawakami Y; Tenjinbaru K; Li P; Walravens K; Gillard P; Roman F
    Hum Vaccin Immunother; 2012 Feb; 8(2):260-6. PubMed ID: 22426369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.